We are live on ! Find out more
ALLO icon

Allogene Therapeutics

172 hedge funds and large institutions have $3.79B invested in Allogene Therapeutics in 2020 Q2 according to their latest regulatory filings, with 66 funds opening new positions, 55 increasing their positions, 37 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

633% more first-time investments, than exits

New positions opened: 66 | Existing positions closed: 9

308% more capital inflows, than outflows

Capital inflows: $711M | Capital outflows: $174M

74% more call options, than puts

Call options by funds: $15.9M | Put options by funds: $9.13M

50% more funds holding

Funds holding: 115 → 172 (+57)

49% more repeat investments, than reductions

Existing positions increased: 55 | Existing positions reduced: 37

40% more funds holding in top 10

Funds holding in top 10: 5 → 7 (+2)

4.77% more ownership

Funds ownership: 59.04% → 63.81% (+4.8%)

Holders
172
Holders Change
+57
Holders Change %
+49.57%
% of All Funds
3.52%
Holding in Top 10
7
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+40%
% of All Funds
0.14%
New
66
Increased
55
Reduced
37
Closed
9
Calls
$15.9​M
Puts
$9.13​M
Net Calls
+$6.78​M
Net Calls Change
+$7.04​M

ALLO Hedge Fund Activity: Q2 2020 in Review

172 of the 4,888 institutional investors tracked by Wall St. Rank reported a position in Allogene Therapeutics (ALLO) for Q2 2020, worth a combined $3.79B — up 164% from $1.44B a quarter earlier.

Buyers outnumbered sellers: 66 funds opened new ALLO positions and 9 closed out — a net gain of 57 holders — while 55 added to existing stakes and 37 trimmed.

The largest buyer was Capital Research Global Investors, adding an estimated $110M. The largest seller was TPG Group Holdings (SBS) Advisors, cutting an estimated $54.2M.

  • 172 institutional investors held Allogene Therapeutics (ALLO) as of Q2 2020, up from 115 in Q1 2020.
  • Funds reported $3.79B of Allogene Therapeutics stock for Q2 2020, up 164% quarter-over-quarter.
  • 66 funds opened new Allogene Therapeutics positions in Q2 2020 and 9 closed out, a net change of +57 holders.
  • The largest Allogene Therapeutics buyer in Q2 2020 was Capital Research Global Investors, an estimated $110M added.
  • The largest Allogene Therapeutics seller in Q2 2020 was TPG Group Holdings (SBS) Advisors, an estimated $54.2M sold.

Based on aggregated 13F filings for Q2 2020.